For the quarter ending 2026-03-31, TOIIW had -$3,285K decrease in cash & cash equivalents over the period. -$3,257K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Unrealized (gain) loss on investments | - | 0 | 0 | 0 |
| Accretion of discount on investment securities | - | 0 | 0 | 0 |
| Net loss | -2,492 | -7,508 | -16,504 | -36,594 |
| Depreciation and amortization | 1,616 | 1,632 | 1,723 | 3,589 |
| Deferred taxes | - | 0 | 0 | -32 |
| Amortization of debt issuance costs and debt discount | 1,211 | 1,205 | 1,172 | 6,003 |
| Write-off of assets from clinical trials segment | - | 0 | 0 | 2,398 |
| Loss on disposal of property and equipment | - | 0 | 0 | 0 |
| Share-based compensation | 1,686 | 1,317 | 1,024 | 2,210 |
| Change in fair value of liability classified warrants | -168 | 1 | 150 | 96 |
| Change in fair value of liability classified conversion option derivatives | 4,996 | 1,067 | -5,977 | -7,296 |
| Accounts receivable | -864 | -641 | 3,980 | 8,969 |
| Other receivables | 994 | -17 | 63 | 228 |
| Inventories | 7,415 | -2,007 | 3,096 | 5,747 |
| Prepaid expenses and other current assets | -144 | -230 | -553 | -1,250 |
| Other assets | 14 | 20 | 0 | -3 |
| Accounts payable | 4,611 | 7,709 | 439 | 11,490 |
| Change in operating leases | -186 | -178 | -154 | -120 |
| Accrued expenses and other current liabilities | 3,918 | -2,837 | 127 | 2,262 |
| Other non-current liabilities | 0 | 84 | 2 | -97 |
| Sales of marketable securities/investments | - | 0 | 0 | 0 |
| Net cash and cash equivalents used in operating activities | -2,215 | 3,233 | -12,630 | -15,190 |
| Purchases of property and equipment | 1,042 | 1,060 | 604 | 1,536 |
| Proceeds from asset disposition | 0 | 0 | 0 | 126 |
| Net cash and cash equivalents used in investing activities | -1,042 | -1,060 | -604 | -1,410 |
| Proceeds from private placement, net of offering costs | 0 | 0 | 0 | 15,359 |
| Proceeds from at-the-market offering, net of offering costs | - | 3,889 | 7,612 | 2,340 |
| Proceeds from employee stock purchase plan | 220 | 0 | 151 | - |
| Payments made for financing of insurance payments | 260 | 300 | 235 | 456 |
| Payment of deferred consideration liability for acquisition | - | 50 | 0 | 0 |
| Principal payments on long-term debt | 0 | 0 | 0 | 20,000 |
| Principal payments on financing leases | 9 | 9 | 8 | 20 |
| Common stock issued for warrants exercised | - | 132 | 385 | - |
| Common stock issued for options exercised | 21 | 72 | 2,695 | - |
| Net cash and cash equivalents used in financing activities | -28 | 3,734 | 10,600 | -2,777 |
| Net decrease in cash and cash equivalents | -3,285 | 5,907 | -2,634 | -19,377 |
| Cash and cash equivalents at beginning of period | 33,565 | 27,658 | 49,669 | - |
| Cash and cash equivalents at end of period | 30,280 | 33,565 | 27,658 | - |
Oncology Institute, Inc. (TOIIW)
Oncology Institute, Inc. (TOIIW)